Scott Braunstein - Feb 4, 2022 Form 4 Insider Report for MARINUS PHARMACEUTICALS INC (MRNS)

Role
Chief Executive Officer, Director
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
Stock symbol
MRNS
Transactions as of
Feb 4, 2022
Transactions value $
$0
Form type
4
Date filed
2/7/2022, 03:08 PM
Previous filing
Dec 21, 2021
Next filing
May 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNS Common Stock Award $0 +42.9K +171.6% $0.00 67.9K Feb 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNS Stock Option (Right to Buy) Award $0 +193K $0.00 193K Feb 4, 2022 Common Stock 193K $10.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2 The option vests and becomes exercisable in 36 equal monthly installments beginning on March 4, 2022.

Remarks:

Exhibit 24: Power of Attorney